Armata Pharmaceuticals, Inc.
AMEX:ARMPBiotechnology
-$0.02 today
- Market cap
- $117.90M
- Beta
- 1.22
- P/E (TTM)
- -0.9
- EPS (TTM)
- -$7.74
Volume 0.09M
Average 0.07M
ARMP Effect of Forex Changes
Change in reported cash caused by exchange-rate movements on foreign-currency balances.
Armata Pharmaceuticals, Inc.AMEX: ARMP
Effect of Forex Changes · Q1 FY2026 · quarter ended Mar 2026
Effect of forex changes outflow grows to $0
Q1 FY2026 effect of forex changes was $0, compared with $0 a year earlier. Trailing-twelve-month effect of forex changes was $0.
Context
- Effect of forex changes amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Effect of forex changes increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly effect of forex changes holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Effect of Forex Changes history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Effect of Forex Changes | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | +100.0% |
| FY2022 | 2022-12-31 | (4.76M) | — |
| FY2021 | 2021-12-31 | 0 | — |
Effect of Forex Changes vs competitors
How ARMP compares with its peers on the latest reported figures
- ARMP's LTM Mar 2026 effect of forex changes of $0 is the largest of the 2 companies compared; the peer median is $0.
- Effect of forex changes amounts to 0.0% of revenue for ARMP, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding ARMP) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (23.16M) | (36.92M) | (69.05M) | (18.92M) | (173.8M) |
| Depreciation & Amortization | 1.17M | 892K | 972K | 1.33M | 1.53M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.88M | 3.11M | 938K | 2.89M | 2.61M |
| Change in Working Capital | (3.22M) | 439K | (9.65M) | (2.1M) | (1.41M) |
| Accounts Receivables | (2.43M) | 1.05M | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 184K | 3.67M | 39K | (3.76M) | (334K) |
| Other Working Capital | (979K) | (4.28M) | (9.69M) | 1.66M | (1.08M) |
| Other Non-Cash Items | (1.25M) | 0 | 29.36M | (20.75M) | 145.31M |
| Operating Cash Flow | (23.58M) | (32.48M) | (47.42M) | (37.55M) | (25.76M) |
| Capital Expenditures | (1.3M) | (2.21M) | (8.14M) | (1.88M) | (542K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 10K | 0 | 0 |
| Investing Cash Flow | (1.3M) | (2.21M) | (8.13M) | (1.88M) | (542K) |
| Debt Repayment | 0 | 0 | 54.03M | 34.89M | 25M |
| Common Stock Issued | 26.32M | 44.52M | 5K | 130K | 658K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (801K) | (500K) | (43K) | (61K) | (46K) |
| Financing Cash Flow | 25.52M | 44.02M | 53.99M | 34.96M | 25.61M |
| Effect of Forex Changes | 0 | (4.76M) | 0 | 0 | 0 |
| Net Change in Cash | 639K | 4.56M | (1.57M) | (4.47M) | (693K) |
| Free Cash Flow | (24.88M) | (34.69M) | (55.57M) | (39.43M) | (26.31M) |
Armata Pharmaceuticals, Inc.
AMEX:ARMP
Intrinsic Alpha fair value
Locked
Current Price
$3.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.